nodes	percent_of_prediction	percent_of_DWPC	metapath
Cinoxacin—SLC22A6—Hydrochlorothiazide—nephrolithiasis	0.883	1	CbGbCtD
Cinoxacin—SLC22A6—Organic anion transport—SLC22A12—nephrolithiasis	0.0502	0.433	CbGpPWpGaD
Cinoxacin—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.0234	0.202	CbGpPWpGaD
Cinoxacin—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00469	0.0404	CbGpPWpGaD
Cinoxacin—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00436	0.0376	CbGpPWpGaD
Cinoxacin—SLC22A6—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00307	0.0265	CbGpPWpGaD
Cinoxacin—SLC22A6—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00281	0.0242	CbGpPWpGaD
Cinoxacin—SLC22A6—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00281	0.0242	CbGpPWpGaD
Cinoxacin—SLC22A6—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00213	0.0184	CbGpPWpGaD
Cinoxacin—SLC22A6—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00213	0.0184	CbGpPWpGaD
Cinoxacin—SLC22A6—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00198	0.0171	CbGpPWpGaD
Cinoxacin—SLC22A6—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00198	0.0171	CbGpPWpGaD
Cinoxacin—SLC22A6—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00176	0.0152	CbGpPWpGaD
Cinoxacin—SLC22A6—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00175	0.0151	CbGpPWpGaD
Cinoxacin—SLC22A6—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00175	0.0151	CbGpPWpGaD
Cinoxacin—SLC22A6—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00156	0.0135	CbGpPWpGaD
Cinoxacin—SLC22A6—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00143	0.0123	CbGpPWpGaD
Cinoxacin—SLC22A6—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00143	0.0123	CbGpPWpGaD
Cinoxacin—SLC22A6—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00108	0.00933	CbGpPWpGaD
Cinoxacin—SLC22A6—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00108	0.00933	CbGpPWpGaD
Cinoxacin—SLC22A6—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00101	0.00868	CbGpPWpGaD
Cinoxacin—SLC22A6—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00101	0.00868	CbGpPWpGaD
Cinoxacin—SLC22A6—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000897	0.00773	CbGpPWpGaD
Cinoxacin—SLC22A6—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000897	0.00773	CbGpPWpGaD
Cinoxacin—SLC22A6—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000717	0.00618	CbGpPWpGaD
Cinoxacin—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	5.97e-05	0.077	CcSEcCtD
Cinoxacin—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	5.06e-05	0.0653	CcSEcCtD
Cinoxacin—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	4.33e-05	0.0559	CcSEcCtD
Cinoxacin—Tinnitus—Hydrochlorothiazide—nephrolithiasis	4.27e-05	0.0551	CcSEcCtD
Cinoxacin—Angioedema—Hydrochlorothiazide—nephrolithiasis	3.65e-05	0.047	CcSEcCtD
Cinoxacin—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	3.26e-05	0.042	CcSEcCtD
Cinoxacin—Oedema—Hydrochlorothiazide—nephrolithiasis	3.26e-05	0.042	CcSEcCtD
Cinoxacin—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	3.19e-05	0.0411	CcSEcCtD
Cinoxacin—Anorexia—Hydrochlorothiazide—nephrolithiasis	3.1e-05	0.04	CcSEcCtD
Cinoxacin—Insomnia—Hydrochlorothiazide—nephrolithiasis	2.95e-05	0.038	CcSEcCtD
Cinoxacin—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	2.92e-05	0.0377	CcSEcCtD
Cinoxacin—Somnolence—Hydrochlorothiazide—nephrolithiasis	2.89e-05	0.0373	CcSEcCtD
Cinoxacin—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	2.83e-05	0.0365	CcSEcCtD
Cinoxacin—Pain—Hydrochlorothiazide—nephrolithiasis	2.78e-05	0.0359	CcSEcCtD
Cinoxacin—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	2.66e-05	0.0344	CcSEcCtD
Cinoxacin—Urticaria—Hydrochlorothiazide—nephrolithiasis	2.59e-05	0.0334	CcSEcCtD
Cinoxacin—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	2.57e-05	0.0332	CcSEcCtD
Cinoxacin—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	2.4e-05	0.031	CcSEcCtD
Cinoxacin—Pruritus—Hydrochlorothiazide—nephrolithiasis	2.3e-05	0.0297	CcSEcCtD
Cinoxacin—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	2.23e-05	0.0287	CcSEcCtD
Cinoxacin—Dizziness—Hydrochlorothiazide—nephrolithiasis	2.15e-05	0.0278	CcSEcCtD
Cinoxacin—Vomiting—Hydrochlorothiazide—nephrolithiasis	2.07e-05	0.0267	CcSEcCtD
Cinoxacin—Rash—Hydrochlorothiazide—nephrolithiasis	2.05e-05	0.0265	CcSEcCtD
Cinoxacin—Dermatitis—Hydrochlorothiazide—nephrolithiasis	2.05e-05	0.0265	CcSEcCtD
Cinoxacin—Headache—Hydrochlorothiazide—nephrolithiasis	2.04e-05	0.0263	CcSEcCtD
Cinoxacin—Nausea—Hydrochlorothiazide—nephrolithiasis	1.93e-05	0.025	CcSEcCtD
